Conventional Synthetic DMARD
PreclinicalSmall molecule
Conventional Synthetic DMARD is one of 34 small molecule programs targeting Rheumatoid Arthritis. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Rituxan
RochePreclinical
Simponi
Johnson & JohnsonPreclinical
Remicade
OOrganon and Co
Preclinical
Enbrel
IImmunex
Preclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSecondWave Systems Inc.